The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
In this video, Antonio Jimenez-Jimenez, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses an analysis of the ACCESS trial (NCT04904588), which evaluated the impact of the degree of human leukocyte antigen (HLA) mismatch on transplantation outcomes in patients with hematological malignancies undergoing a mismatched unrelated donor (MMUD) transplant. Dr Jimenez-Jimenez highlights that, when using post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GvHD) prophylaxis, outcomes for patients receiving highly mismatched grafts were comparable to those of patients receiving a single antigen-mismatched graft. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
